Comparison · NCT02243605-sae
Osteosarcoma vs Ewing Sarcoma: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Osteosarcoma vs Ewing Sarcoma: serious adverse events. Trial comparisons, record NCT02243605-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02243605-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.521 | 0.786 | wilson | |
| Risk in group 2 | 0.689 | 0.543 | 0.805 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0222 | -0.209 | 0.166 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.968 | 0.728 | 1.29 | log | |
| Odds ratio, group 1 over group 2 | 0.903 | 0.373 | 2.19 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Osteosarcoma than on Ewing Sarcoma | 45 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Osteosarcoma | Patients receive cabozantinib s-malate PO QD on days 1-28. 60 mg for patients ≥ 16 years and 40mg/m² for patients ≥ 12 years and \<16 years. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 30 | 45 | EG000 |
| Group 2 | Ewing Sarcoma | Patients receive cabozantinib s-malate PO QD on days 1-28. 60 mg for patients ≥ 16 years and 40mg/m² for patients ≥ 12 years and \<16 years. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 31 | 45 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Safety profile was continuously followed during treatment and up to 30 days after the last Cabozantinib dose or until the start of a new antitumor therapy, whichever occurs first.
Source ClinicalTrials.gov
Trial
- Title
- Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
- NCT number
- NCT02243605
- Phases
- PHASE2
- Conditions
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma, Stage III Osteosarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Unresectable Ewing Sarcoma, Unresectable Osteosarcoma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2020-09-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02243605?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02243605-sae